Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
The paper is attached!!! The field that is being referred to is based on the paper. For the written portion, you will write on any of the primary articles. I am expecting everyone to turn in a three (
The paper is attached!!! The field that is being referred to is based on the paper.
For the written portion, you will write on any of the primary articles. I am expecting everyone to turn in a three (3) page document that includes the following:
1) A few sentences that explain the current understanding of the field -- concise but information-packed -- What do we know?
2) A transition paragraph explaining the gaps in knowledge that remain unanswered -- What do we want to know?
3) A section outlining one (1) aim and some proposed experiments that can help answer the field's questions.
- An aim is defined as the desired outcome - What do you want to achieve from your proposed experiments? This could be understanding how a drug interacts with a certain type of cell, or if a certain treatment causes a specific type of damage. We will talk more about this in class tomorrow.
4) Impact statement -- why are your proposed experiments important? Will the results of this study save lives/or change the field forever?
5) Citations -- APA format! You can use a citation manager for this (I use Microsoft EndNote, but Easybib.com works just as well)
Think about the language that scientists use when they are writing papers -- how do scientists speak about what they've done? How do they speak about future experiments? I have attached an example of my old writing so that you have a template to work with. Remember, I'm not expecting you to get a Nobel prize, I just want you to try to write like a scientist. Give it your best effort, and don't be afraid to ask for help! :)
For this portion of the final project, you will be graded based on the following:
- Content (25 points) - Concise and complete body of work vs "word salad"
- Grammar (25 points) - Complete sentences, good transitions, no typos
- Science (25 points) - Are your proposed experiments feasible? Do you understand what the results of your proposed experiments would mean? What would the proposed experiments add to the study?
- @
- 53 orders completed
- ANSWER
-
Tutor has posted answer for $20.00. See answer's preview
************** NameCourseDateWee1 kinase ********* **************** ********** ****** ********* ********* induces ********* ** acute lymphoblastic leukemia cells *** enhances *** efficacy of *********** ********* ************** ** *** Notch ********************* ******** ************* ** *** field)Cancer ****** **** ***** ** *** body increase uncontrollably There *** several ***** of ****** ********* ***** *** ******* ** practically *** region of *** **** ********* are ************ that begin in ***** that typically divide *** ************* into ******* ***** ** blood ***** Most ********* ********* ** leucocyteprecursors although **** ***** ** ***** ***** ****** ******** ******** ******** is characterized ** ******* ********** or gradually ********** ***** ******** ****** ** monocyte ** lymphatic ****** ***** lymphocytic ******** (ALL) ** * **** ** ******** known ** ***** lymphoblastic ******** *** term ******* ****** ** ******** that may spread ******* and ** **** untreated is ****** ** be **** ***** * ****** ** ***** ************* ****** to ** ******* **** *** fully ********* *********** ****************** ** * micro ********* component **** inhibitor **** is ******** and ********* Various ******* ********* ** increase *** *************** ********* **************** ***** carboplatin and ********* ** ************* ********* ***** ************ is * frequent treatment ****** *** * wide ***** of solid ******* 4 **** ** ********* in *********** *** **** checkpoint and *** *** ********* ********* ********* ******* ** regulates *** *************** ** ****** ** *** **** ***** ****** **** ***** ******** ***** **** ********** *** **** shown ** ******* ******* *********** ** ******* *********** ******** *** **** ********** ************ improving **** *********** ** *** Cytotoxic ****** **** inhibition has **** been shown ** ******* ************* susceptibility ** ********** ****** ******** ** DNA ************ is ********** as an anthracycline * **** ** chemotherapy ********** ** ******** the development ** ********* ***** ** ********** *** activity ** ** ****** ***** ** ************* * * **** ****** ** ******** *** *** ******** *** ****** ** cancer ***** ** ***** by ********** ************* ** ***** ********* *** following ************* ******** ************* ** *** DNA ************* **** ** a ****** limiting *** *********** *********** is ** *********** drug 3 ***** signaling is * *************** ******* that **** *** ******* any ********* ********* ** * ********* ** ****** ********* *** **** ** & Xiao ***** ******* "Jagged" *** "Delta" ********* ****** on a ****** cell *** connect **** ***** transmembrane ********* on * *********** **** ***** ********* helps ************* ** **** efficient3 *** suppress **** ****** ** ******** growth ****** in the **** ***** *** **** death ** *** ******** of *** ******** Furthermore *** administration ************* ********* *** expression *** ******* activation ********* ** ********* ************* ********* signaling *** **** ***** 2 Wee1 regulates *********** *** *************** *** chromosome ********* ** is ******** *** ****** cell ************* Wee1 is * ** KD ******* *********** **** belongs ** *** Ser/Thr family ** ********* pathways ******** ********* **** ******* ********** (the Gap)It ** identified **** *** Wee1 ********* **** ******* ********* of *** **** ALL *** ******** the ******** of *** the downregulation ** *** ******* ******** the ***** ******* ******* **** ************** ******* **** ****** ********** the ********** ** ***** the *** ****** ********* ******* ******* *** **** ***** of ALL ***** Another *** **** ****** when ADM ** **** ** there are any ******* ** *** **************** agent on the Notch ********** hence ** ******** ** *** ** ***** ********* ** ******** to ********* whether ***** *** *********** ******* ** *** ****** ****** ******** *** **** ** *** ***** signaling ******* *** the ******** ** **** ****** ********* ********* ** brought ** concerning *** ** *** ********* ** ALL ****** ******** ** **** ** ******** the mutations **** ***** with *** ***** * receptor ** Notch ********* ** essential *** ***** *** progression ** *** ************* *** ********** ** the ******* is crucial ** *** determination ** inhibition ** ALL cell proliferationSpecific *********** lymphoblastic ******** ***** ** ** aggressive hematopoietic ****** **** affects ******** *** adult ******** ********* oncogenic potential ** being ************ ** ******* ******** alone and ******** with the ********** ADM ********* ** ********* *** cells ***** treatment **** ******* ***** isrelated ** unexpected ******* initiation *** ********* ***** ******* expression MK-1775 ************ ************* activity **** is * **** **** ***** ******* kinase that ******** ******** ************* *** ****** ********* ** ** ******** *** ******* **** ****** and *********** ** ****** years ** *** **** ***** **** MK-1775 * specific antagonist ** Wee1 *** trigger **** ***** ** ********* ***** ** ********** *** G2/M ***** ** antagonist ** *** Wee1 ******* MK-1775 *** ***** ******** ***** activity ** ******** ******* ******** *** ******* ********** ** *** ***** ******* ************* *** specific mechanism ** ********* by Wee Kinase inhibitor MK-1775 ** ******** in *** whole ******* ** *** controlThe ******* objective ** ** ****** *** mechanism ** which *** *** ****** ********* ******* ******* ALL ****** **** ***** ******* ** *** *********** ** *** **** ******** **** **** **** ADM ********* ******* *** *** Our central ********** ** **** ******* caused ********* activity ** cells *** ******** *********** ******* ******** ************* ****** ********** of the Notch ****** ***** other ********** Based on our ********** ******* ******* the ****** ***** resultsin the induction ** **** ***** shown ** the ********* ** ****** *** an ******** transcriptional ************ ********** *** ** determine ******** ********* *** *********** efficacy in ********* induction ** **** ****** ********* ********* and *** In ALL **** ********* *********** **** ** Wee1 ****** ********* MK‑1775 apoptosis induction ** *** enhancement ** *********** ** the downregulation ** *** ***** pathway ** ********** **** *** ********* or therapeutic ********** *** ** to ********* if **** kinase inhibitor ********* ********* ********* ** the *********** ** doxorubicin ** *** ************** of *** ***** ******* ** ********** with *** mutations ** therapeutic effectsWe *********** that ** **** kinase ********* ********* ********* ********* ** *** enhancement of doxorubicin ** *** downregulation ** *** notch ******* ** ********** **** *** ********* or *********** ********* **** detect ** ***** are ****** or ********** ** DNA using the ***** ***** method ***** was **** by *** ******* manual ********* cell ********** lysis on **** **** * microscope ***** is ********* ** * nutshell *** *************** ********* **** ** ********* *** ****** ******* *** the ****** *** ************ mounted and allowed ** *** naturally *** ****** **** ************ stained **** cyber ***** and examined *** **** *********** ******** *** *** ******* * ************** ****** *** DNA ****** ** determined by *** ******** ********* and ******* ** *** ************ *************** cell ******* ********** *** *********** ********** Wee inhibitor MK-1775 **** ** ********* ** DMSO *** added to ***** with the ***** ************** we will **** this **** ***** ** ******* ********** *** growth *** cell ********* ** will ***** ***** **** ******* *** *********** or ******* them **** *********** ** * ***** ***** ***** **** ** **** *** *** *********** hours For *** ** vivo study *** ***** ******** **** ** ***** to ******** ***** ** will ****** them to ****** together **** *********** *** 18 hours We will ******* *** ****** fragments *** ********** ******* *** western blot ****************** two: ** ********* how ********** ** the ***** pathway ** ******* out during *** ALL **** ******* ********** ** *** *********** ** **** ****** ********* MK‑1775 and ADMWe hypothesize **** *** ***** ********* involved ** NOTCH signaling ********** ******* ALL **** ********** ********* this hypothesis *** ******** **** ******* *********** ** ***** **** **** one ******* ** ***** ******* ** MK-1775 *** ** hours ** investigate *** ********* ** ******* ** the cell ***** ********** ** ALL ********* done invitro ********** the ***** *** staining **** **** ** will be **** **** ** *** test ** ********** the **** cycle Impact *** treatment of ALL ** ******** *** understanding ** ***** are any **** ******* ******** **** *** **** ********* **** ** apoptosis ********* and *** in ***** ******* ********** **** ************* the ********** ** *** ******* ********* ******** *** best **** *** *** treatment ************* both ***** scientific approaches is ******* ** developing the best ******* for ******************** **** * **** * Nie * ** ** Wee1 kinase ********* ********* ******* ********* ** ***** ************* ******** ***** and ******** *** efficacy ** doxorubicin ********* ************** ** Notch pathwayOncol **** **** doi:103892/ol201892912 ******** * *** * **** * Ye * **** * **************** ***** doxorubicin ****** ******* gene ********** ** ******** ** ******** ** ************** CD-1 ***** *********** Reprod 2018;100(4):869-871 ************************* *** * ** L ** * ** ** *********** ********* *** ***** ********* pathway ** osteosarcomaOncol **** ******************* ********************** ***** J Pear W ******** * ***** ********* in ************** ****** ** Pathology: ********** ** ******* 2008;3(1):587-613 doi:101146/annurevpathmechdis31218061543005 Terwilliger T ********* * Acute ************* ********* * ************* ****** and **** *********** ****** * ******************* ******************************************** * *** * **** * ** X ***** **** * ****** **************** ***** *********** ****** ******* **** expression ** ******** ** estrogen ** ************** **** ***** ************** ** ****************** ******* doi: 101093/boiler/ioy259Aster * Pear * ***** ******** S (2008) ***** ********* in ************** ****** ** ********** Mechanisms ** *********** 587-613 **** ****************************************** * **** X Nie * Li P Lu F ** * ***** ** * ****** **** ****** inhibitor ********* ******* ********* ** ***** lymphoblastic ******** cells *** ******** *** ******** of doxorubicin ********* ************** ** *** ***** *************** ******* doi: 103892/ol20189291MEI H ** L JI P **** * **** * ***** *** * ** al ****** *********** ********* the ***** ********* ******* ** ******************** *********** ********* **** **************************** T ***** ********* M (2017) ***** ************* ********* a ************* ****** and 2017 updateBlood ****** *********** e577-e577 doi: ****************************************************************